NewAmsterdam Pharma Co N.V annual r&d spending
2021
2022
2023
2024
2025
NewAmsterdam Pharma Co N.V R&D Spending Growth & History (NAMS)
NewAmsterdam Pharma Co N.V's r&d spending was $141.8M for fiscal 2025.
View full NewAmsterdam Pharma Co N.V company overviewNewAmsterdam Pharma Co N.V annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $141.8M | −$9.6M | −6.32% |
| 2024 | 2024-12-31 | $151.4M | −$8.0M | −5.03% |
| 2023 | 2023-12-31 | $159.4M | $72.7M | +83.79% |
| 2022 | 2022-12-31 | $86.7M | $57.8M | +199.39% |
| 2021 | 2021-12-31 | $29.0M | — | — |
NewAmsterdam Pharma Co N.V quarterly r&d spending
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $41.7M | $14.2M | +51.45% |
| Q1 2026 | 2026-03-31 | $38.0M | −$6.7M | −15.07% |
| Q4 2025 | 2025-12-31 | $38.6M | $3.7M | +10.60% |
| Q3 2025 | 2025-09-30 | $31.0M | −$4.7M | −13.25% |
| Q2 2025 | 2025-06-30 | $27.5M | −$10.9M | −28.30% |
| Q1 2025 | 2025-03-31 | $44.8M | $2.3M | +5.47% |
| Q4 2024 | 2024-12-31 | $34.9M | −$6.4M | −15.49% |
| Q3 2024 | 2024-09-30 | $35.7M | −$7.7M | −17.68% |
| Q2 2024 | 2024-06-30 | $38.4M | $4.0M | +11.76% |
| Q1 2024 | 2024-03-31 | $42.4M | $2.0M | +4.97% |
| Q4 2023 | 2023-12-31 | $41.3M | — | — |
| Q3 2023 | 2023-09-30 | $43.4M | — | — |
| Q2 2023 | 2023-06-30 | $34.3M | — | — |
| Q1 2023 | 2023-03-31 | $40.4M | — | — |
NewAmsterdam Pharma Co N.V r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, NewAmsterdam Pharma Co N.V's r&d spending increased from $29.0M to $141.8M, a change of $112.9M. The latest reported quarter, Q2 2026, shows $41.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NewAmsterdam Pharma Co N.V source filings ↗